Day One Biopharmaceuticals Shares Rally on FDA Priority Review
By Colin Kellaher
Day One Biopharmaceuticals shares rose sharply Monday after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted priority review to its application seeking approval of its lead product candidate.
Shares of the Brisbane, Calif., company were recently changing hands at $11.49, up 13%.
Day One is seeking an FDA green light for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma, the most common brain tumor diagnosed in children.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Day One said there is currently no standard of care and no approved therapy for the vast majority of pediatric low-grade glioma patients in the relapsed setting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2023 10:39 ET (14:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?